Literature DB >> 28321640

How Qualitative Methods Can be Used to Inform Model Development.

Samantha Husbands1, Susan Jowett2, Pelham Barton2, Joanna Coast3.   

Abstract

Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modellers find most challenging. Further, it is important that modelling methods and related guidance are continually updated in light of any new approaches that could potentially enhance model credibility. The objective of this article was to highlight the ways in which qualitative methods have been used and recommended to inform decision-analytic model development and enhance modelling practices. With reference to the literature, the article discusses two key ways in which qualitative methods can be, and have been, applied. The first approach involves using qualitative methods to understand and inform general and future processes of model development, and the second, using qualitative techniques to directly inform the development of individual models. The literature suggests that qualitative methods can improve the validity and credibility of modelling processes by providing a means to understand existing modelling approaches that identifies where problems are occurring and further guidance is needed. It can also be applied within model development to facilitate the input of experts to structural development. We recommend that current and future model development would benefit from the greater integration of qualitative methods, specifically by studying 'real' modelling processes, and by developing recommendations around how qualitative methods can be adopted within everyday modelling practice.

Mesh:

Year:  2017        PMID: 28321640     DOI: 10.1007/s40273-017-0499-z

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  22 in total

1.  The appropriate uses of qualitative methods in health economics.

Authors:  J Coast
Journal:  Health Econ       Date:  1999-06       Impact factor: 3.046

2.  Qualitative research: standards, challenges, and guidelines.

Authors:  K Malterud
Journal:  Lancet       Date:  2001-08-11       Impact factor: 79.321

Review 3.  Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.

Authors:  Zoë Philips; Laura Bojke; Mark Sculpher; Karl Claxton; Su Golder
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose.

Authors:  William Sullivan; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

Review 5.  A Systematic Review of Research Guidelines in Decision-Analytic Modeling.

Authors:  Maria Cristina Peñaloza Ramos; Pelham Barton; Sue Jowett; Andrew John Sutton
Journal:  Value Health       Date:  2015-02-07       Impact factor: 5.725

6.  Identification and review of cost-effectiveness model parameters: a qualitative study.

Authors:  Eva Kaltenthaler; Munira Essat; Paul Tappenden; Suzy Paisley
Journal:  Int J Technol Assess Health Care       Date:  2014-08-04       Impact factor: 2.188

7.  Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.

Authors:  Mark Roberts; Louise B Russell; A David Paltiel; Michael Chambers; Phil McEwan; Murray Krahn
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

8.  Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting.

Authors:  Stavros Petrou; Alastair Gray
Journal:  BMJ       Date:  2011-04-11

9.  Whither trial-based economic evaluation for health care decision making?

Authors:  Mark J Sculpher; Karl Claxton; Mike Drummond; Chris McCabe
Journal:  Health Econ       Date:  2006-07       Impact factor: 3.046

10.  Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations.

Authors:  Cynthia P Iglesias; Alexander Thompson; Wolf H Rogowski; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

View more
  7 in total

Review 1.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

2.  Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study.

Authors:  Samantha Husbands; Susan Jowett; Pelham Barton; Joanna Coast
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

3.  Health state utilities for beta-thalassemia: a time trade-off study.

Authors:  Antony P Martin; Enrico Ferri Grazzi; Claudia Mighiu; Manoj Chevli; Farrukh Shah; Louise Maher; Anum Shaikh; Aliah Sagar; Hayley Hubberstey; Bethany Franks; Juan M Ramos-Goñi; Mark Oppe; Derek Tang
Journal:  Eur J Health Econ       Date:  2022-03-26

4.  Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.

Authors:  Kate M Johnson; Boshen Jiao; M A Bender; Scott D Ramsey; Beth Devine; Anirban Basu
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.752

5.  Quantifying the Impact of Capacity Constraints in Economic Evaluations: An Application in Precision Medicine.

Authors:  Stuart J Wright; William G Newman; Katherine Payne
Journal:  Med Decis Making       Date:  2021-10-25       Impact factor: 2.583

6.  Structuring a conceptual model for cost-effectiveness analysis of frailty interventions.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Olga Theou; Justin Beilby; Matteo Cesari; Renuka Visvanathan
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

7.  Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values.

Authors:  Sarah Costa; Dean A Regier; Adam J N Raymakers; Samantha Pollard
Journal:  Patient       Date:  2021-03       Impact factor: 3.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.